Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus

Jordan M. Schecter, J. Gregory Mears, Bachir Alobeid, Paul J. Gaglio

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

After liver transplantation, reinfection of the newly engrafted liver with hepatitis C virus is essentially universal in patients who are viremic at the time of transplantation. Treatment with interferon preparations with or without ribavirin is recommended in patients with marked histologic injury; however, hematologic toxicity associated with therapy has been reported, which is usually treated with growth factor support, including erythropoietin analogues. We present the first reported case of antierythropoietin antibody-mediated pure red cell aplasia arising in the setting of hepatitis C virus therapy in a patient who underwent living donor liver transplantation.

Original languageEnglish (US)
Pages (from-to)1589-1592
Number of pages4
JournalLiver Transplantation
Volume13
Issue number11
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Pure Red-Cell Aplasia
Living Donors
Erythropoietin
Hepacivirus
Anti-Idiotypic Antibodies
Liver Transplantation
Liver
Ribavirin
Interferons
Intercellular Signaling Peptides and Proteins
Therapeutics
Transplantation
Antibodies
Wounds and Injuries
Transplant Recipients

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus. / Schecter, Jordan M.; Mears, J. Gregory; Alobeid, Bachir; Gaglio, Paul J.

In: Liver Transplantation, Vol. 13, No. 11, 11.2007, p. 1589-1592.

Research output: Contribution to journalArticle

Schecter, Jordan M. ; Mears, J. Gregory ; Alobeid, Bachir ; Gaglio, Paul J. / Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus. In: Liver Transplantation. 2007 ; Vol. 13, No. 11. pp. 1589-1592.
@article{596855e339664916aaef841d5ce2cb1e,
title = "Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus",
abstract = "After liver transplantation, reinfection of the newly engrafted liver with hepatitis C virus is essentially universal in patients who are viremic at the time of transplantation. Treatment with interferon preparations with or without ribavirin is recommended in patients with marked histologic injury; however, hematologic toxicity associated with therapy has been reported, which is usually treated with growth factor support, including erythropoietin analogues. We present the first reported case of antierythropoietin antibody-mediated pure red cell aplasia arising in the setting of hepatitis C virus therapy in a patient who underwent living donor liver transplantation.",
author = "Schecter, {Jordan M.} and Mears, {J. Gregory} and Bachir Alobeid and Gaglio, {Paul J.}",
year = "2007",
month = "11",
doi = "10.1002/lt.21332",
language = "English (US)",
volume = "13",
pages = "1589--1592",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus

AU - Schecter, Jordan M.

AU - Mears, J. Gregory

AU - Alobeid, Bachir

AU - Gaglio, Paul J.

PY - 2007/11

Y1 - 2007/11

N2 - After liver transplantation, reinfection of the newly engrafted liver with hepatitis C virus is essentially universal in patients who are viremic at the time of transplantation. Treatment with interferon preparations with or without ribavirin is recommended in patients with marked histologic injury; however, hematologic toxicity associated with therapy has been reported, which is usually treated with growth factor support, including erythropoietin analogues. We present the first reported case of antierythropoietin antibody-mediated pure red cell aplasia arising in the setting of hepatitis C virus therapy in a patient who underwent living donor liver transplantation.

AB - After liver transplantation, reinfection of the newly engrafted liver with hepatitis C virus is essentially universal in patients who are viremic at the time of transplantation. Treatment with interferon preparations with or without ribavirin is recommended in patients with marked histologic injury; however, hematologic toxicity associated with therapy has been reported, which is usually treated with growth factor support, including erythropoietin analogues. We present the first reported case of antierythropoietin antibody-mediated pure red cell aplasia arising in the setting of hepatitis C virus therapy in a patient who underwent living donor liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=36448960894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36448960894&partnerID=8YFLogxK

U2 - 10.1002/lt.21332

DO - 10.1002/lt.21332

M3 - Article

VL - 13

SP - 1589

EP - 1592

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 11

ER -